(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 April 2006 (06.04.2006)

PCT

(10) International Publication Number
WO 2006/036927 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 7/02* (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:
PCT/US2005/034512

(22) International Filing Date:
27 September 2005 (27.09.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/613,656	28 September 2004 (28.09.2004)	US
11/235,519	26 September 2005 (26.09.2005)	US

(71) Applicant *(for all designated States except US)*: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543-4000 (US).

(72) Inventors; and


(75) Inventors/Applicants *(for US only)*: **GLEESON, Margaret M.** [US/US]; 121 Lorraine Drive, Berkeley Heights, New Jersey 07922 (US). **MCGEORGE, Gary** [GB/US]; 1 Coral Court, Franklin Park, New Jersey 08823 (US). **CHEN, Bang-Chi** [US/US]; 28 Marion Drive, Plainsboro, New Jersey 08536 (US). **ZHANG, Huiping** [CN/US]; 9 Hudnut Lane, Belle Mead, New Jersey 08502 (US). **MALLEY, Mary F.** [US/US]; 50 Merion Place, Lawrenceville, New Jersey 08648 (US). **DIMARCO, John D.** [US/US]; 16 Neal Drive, East Brunswick, New Jersey 08816 (US). **MURPHY, Denette K.** [US/US]; 29-H Chicopee Drive, Princeton, New Jersey 08540 (US). **YIN, Xiaotian S.** [CA/US]; 18 Paddock Drive, Plainsboro, New Jersey 08536 (US). **FABIAN, Steven R.** [US/US]; 15 Periwinkle Drive, Barnegat, New Jersey 08005 (US). **GUPTA, Jasmine M.** [IN/US]; 4203 Twin Oaks Court, Monmouth Junction, New Jersey 08852 (US).

(74) Agents: **SUN, Jing G.** et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO,

[Continued on next page]

(54) Title: CRYTALLINE FORMS OF A PYRAZOLO '3, 4-C ! PYRIDINE FACTOR XA INHIBITOR



*** indicates spinning sidebands (artifacts)**

(57) Abstract: The instant invention provides crystalline forms of 1-(3-chlorophenyl)-7-oxo-6-[4-(2-oxo-1(2H)pyridinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide and its solvates thereof; processes for the production of such crystalline forms; pharmaceutical compositions comprising such crystalline forms; and methods of treating thromboembolic disorders with such crystalline forms or such pharmaceutical compositions.

WO 2006/036927 A1

NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	**FOR FURTHER ACTION**	see Form PCT/ISA/220 as well as, where applicable, item 5 below.
10387 - PCT		
International application No.	International filing date *(day/month/year)*	(Earliest) Priority Date *(day/month/year)*
PCT/US2005/034512	27/09/2005	28/09/2004
Applicant		
BRISTOL-MYERS SQUIBB COMPANY		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

[X] It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**
   a. With regard to the **language,** the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
      [ ] The international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
   b. [ ] With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, see Box No. I.

2. [ ] **Certain claims were found unsearchable** (See Box II).

3.

4.

CRYTALLINE FORMS OF A PYRAZOLO'3,4-C!PYRIDINE FACTOR XA INHIBITOR

5. With regard to the **abstract,**
   [X] the text is approved as submitted by the applicant.
   [ ] the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. With regard to the **drawings,**
   a. the figure of the **drawings** to be published with the abstract is Figure No. _____
      [ ] as suggested by the applicant.
      [ ] as selected by this Authority, because the applicant failed to suggest a figure.
      [ ] as selected by this Authority, because this figure better characterizes the invention.
   b. [ ] none of the figures is to be published with the abstract.